Second Line Treatment of Non-Small Cell Lung Cancer: Clinical; Pathological and Molecular Aspects of Novel Promising Drugs

Lung cancer still remains a challenging disease with a higher mortality rate in comparison to other cancers. The discovery of oncogene addicted tumours and targeted therapies responsive to these targets lead to a meaningful change in the prognosis of these diseases. Unfortunately, these newer therap...

Descripción completa

Detalles Bibliográficos

Autores principales:	Umberto Malapelle, Pierlorenzo Pallante
Formato:	Online
Lenguaje:	inglés
Publicado:	Frontiers Media SA 2021
Materias:	R5-920 Alectinib Liquid Biopsy Non-Small Cell Lung Cancer Afatinib Nivolumab Immunotherapy Nintedanib Dacomitinib Second-Line Treatment Tyrosine Kinase Inhibitor thema EDItEUR::M Medicine and Nursing
Acceso en línea:	25575
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!